Skip to main content
Erschienen in: Clinical Rheumatology 12/2014

01.12.2014 | Original Article

Serum complement C3 correlates with insulin resistance in never treated psoriatic arthritis patients

verfasst von: Francesco Ursini, Alessandro Grembiale, Saverio Naty, Rosa Daniela Grembiale

Erschienen in: Clinical Rheumatology | Ausgabe 12/2014

Einloggen, um Zugang zu erhalten

Abstract

The objective of this cross-sectional study is to investigate the relationship between inflammatory markers (C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), white blood cell (WBC) count, and complement C3) and insulin resistance (estimated with the surrogate measure homeostasis model assessment of insulin resistance (HOMA-IR)) in Psoriatic arthritis (PsA) patients. Sixty-seven patients with PsA and 138 age- and sex-matched controls were recruited from the Rheumatology Outpatient Clinic of the University of Catanzaro, Catanzaro (Italy). Plasma glucose, insulin, triglycerides, total cholesterol, LDL cholesterol, and high-density lipoprotein (HDL) cholesterol were measured after at least 12-h fasting. CRP was measured by a high-sensitivity turbidimetric immunoassay. ESR was measured by capillary photometry. Serum C3 and C4 were measured by nephelometry. Insulin resistance was estimated using the original HOMA as reported by Matthews et al. (Diabetologia 28(7):412–419, 1985) from overnight fasting insulin and glucose values, with the following formula: HOMA-IR = glucose (in milligrams per deciliter) × insulin (in micro units per milliliter)/405. Patients and controls had similar body mass index (BMI), blood pressure, and fasting glucose, but fasting serum insulin was higher in PsA patients (median (interquartile range (IQR)) 12.96 (6.35–24.65) for PsA and 10.37 (6.97–15.11) for controls; p = 0.005). Consequently, also the surrogate measure of insulin resistance HOMA-IR was significantly higher in patients (median (IQR) 3.77 (1.58–5.18) for PsA and 2.33 (1.67–3.62) for controls; p = 0.008). In univariate analysis, ln(HOMA-IR) correlated positively with BMI, systolic blood pressure (sBP), dBP, ln(TG), WBC, ln(ESR), ln(CRP) and C3, while correlated negatively with total and HDL cholesterol. In multiple linear regression analysis including age, sex and BMI, serum C3 reached the higher standardized β coefficient, while among other variables only ln(ESR) maintained a weak correlation with ln(HOMA-IR) when sBP was added to the model. When all variables were inserted in a single model, only C3 was independently correlated with ln(HOMA-IR). In a stepwise multiple regression model, serum C3 was selected as the strongest single contributing variable. The model explained 61 % of the variance in ln(HOMA-IR) (R 2 = 0.61). Insulin resistance, estimated with the surrogate measure HOMA-IR, is higher in PsA patients compared to age- and sex-matched controls. Serum C3 could represent a simple marker of insulin resistance in psoriatic arthritis patients.
Literatur
2.
Zurück zum Zitat Boehncke WH, Boehncke S (2012) Cardiovascular mortality in psoriasis and psoriatic arthritis: epidemiology, pathomechanisms, therapeutic implications, and perspectives. Curr Rheumatol Rep 14(4):343–348PubMedCrossRef Boehncke WH, Boehncke S (2012) Cardiovascular mortality in psoriasis and psoriatic arthritis: epidemiology, pathomechanisms, therapeutic implications, and perspectives. Curr Rheumatol Rep 14(4):343–348PubMedCrossRef
3.
Zurück zum Zitat Arumugam R, McHugh NJ (2012) Mortality and causes of death in psoriatic arthritis. J Rheumatol Suppl 89:32–35PubMedCrossRef Arumugam R, McHugh NJ (2012) Mortality and causes of death in psoriatic arthritis. J Rheumatol Suppl 89:32–35PubMedCrossRef
4.
Zurück zum Zitat Jon Love T et al (2012) Obesity and the risk of psoriatic arthritis: a population-based study. Ann Rheum Dis 71(8):1273–1277CrossRef Jon Love T et al (2012) Obesity and the risk of psoriatic arthritis: a population-based study. Ann Rheum Dis 71(8):1273–1277CrossRef
7.
Zurück zum Zitat Tam LS et al (2008) Subclinical carotid atherosclerosis in patients with psoriatic arthritis. Arthritis Rheum 59(9):1322–1331PubMedCrossRef Tam LS et al (2008) Subclinical carotid atherosclerosis in patients with psoriatic arthritis. Arthritis Rheum 59(9):1322–1331PubMedCrossRef
8.
Zurück zum Zitat Azfar RS et al (2012) Increased risk of diabetes mellitus and likelihood of receiving diabetes mellitus treatment in patients with psoriasis diabetes mellitus and psoriasis. Arch Dermatol 148(9):995–1000PubMedCentralPubMedCrossRef Azfar RS et al (2012) Increased risk of diabetes mellitus and likelihood of receiving diabetes mellitus treatment in patients with psoriasis diabetes mellitus and psoriasis. Arch Dermatol 148(9):995–1000PubMedCentralPubMedCrossRef
9.
Zurück zum Zitat Tam LS et al (2008) Cardiovascular risk profile of patients with psoriatic arthritis compared to controls—the role of inflammation. Rheumatology (Oxford) 47(5):718–723CrossRef Tam LS et al (2008) Cardiovascular risk profile of patients with psoriatic arthritis compared to controls—the role of inflammation. Rheumatology (Oxford) 47(5):718–723CrossRef
10.
Zurück zum Zitat Jamnitski A et al (2012) Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis 72(2):211–216PubMedCrossRef Jamnitski A et al (2012) Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis 72(2):211–216PubMedCrossRef
11.
Zurück zum Zitat Reaven GM (1988) Banting lecture, 1998. Role of insulin resistance in human disease. Diabetes 37(12):1595–1607PubMedCrossRef Reaven GM (1988) Banting lecture, 1998. Role of insulin resistance in human disease. Diabetes 37(12):1595–1607PubMedCrossRef
12.
Zurück zum Zitat Reilly MP, Rader DJ (2003) The metabolic syndrome: more than the sum of its parts? Circulation 108(13):1546–1551PubMedCrossRef Reilly MP, Rader DJ (2003) The metabolic syndrome: more than the sum of its parts? Circulation 108(13):1546–1551PubMedCrossRef
13.
Zurück zum Zitat DeFronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237(3):E214–E223PubMed DeFronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237(3):E214–E223PubMed
14.
Zurück zum Zitat Matthews DR et al (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412–419PubMedCrossRef Matthews DR et al (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412–419PubMedCrossRef
15.
Zurück zum Zitat Gisondi P et al (2007) Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case–control study. Br J Dermatol 157(1):68–73PubMedCrossRef Gisondi P et al (2007) Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case–control study. Br J Dermatol 157(1):68–73PubMedCrossRef
16.
Zurück zum Zitat Love TJ et al (2011) Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003–2006. Arch Dermatol 147(4):419–424PubMedCentralPubMedCrossRef Love TJ et al (2011) Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003–2006. Arch Dermatol 147(4):419–424PubMedCentralPubMedCrossRef
17.
Zurück zum Zitat Balci A et al (2010) Increased amount of visceral fat in patients with psoriasis contributes to metabolic syndrome. Dermatology 220(1):32–37PubMedCrossRef Balci A et al (2010) Increased amount of visceral fat in patients with psoriasis contributes to metabolic syndrome. Dermatology 220(1):32–37PubMedCrossRef
18.
Zurück zum Zitat Ucak S et al (2006) Comparison of various insulin sensitivity indices in psoriatic patients and their relationship with type of psoriasis. J Eur Acad Dermatol Venereol 20(5):517–522PubMedCrossRef Ucak S et al (2006) Comparison of various insulin sensitivity indices in psoriatic patients and their relationship with type of psoriasis. J Eur Acad Dermatol Venereol 20(5):517–522PubMedCrossRef
19.
Zurück zum Zitat Martinez-Abundis E et al (2007) Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus. Arch Dermatol Res 299(9):461–465PubMedCrossRef Martinez-Abundis E et al (2007) Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus. Arch Dermatol Res 299(9):461–465PubMedCrossRef
20.
Zurück zum Zitat Taylor W et al (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54(8):2665–2673PubMedCrossRef Taylor W et al (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54(8):2665–2673PubMedCrossRef
21.
Zurück zum Zitat van der Heijde DM et al (1992) Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis 51(2):177–181PubMedCentralPubMedCrossRef van der Heijde DM et al (1992) Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis 51(2):177–181PubMedCentralPubMedCrossRef
22.
Zurück zum Zitat Garrett S et al (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21(12):2286–2291PubMed Garrett S et al (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21(12):2286–2291PubMed
23.
Zurück zum Zitat Calin A et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21(12):2281–2285PubMed Calin A et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21(12):2281–2285PubMed
24.
Zurück zum Zitat Stern SE et al (2005) Identification of individuals with insulin resistance using routine clinical measurements. Diabetes 54(2):333–339PubMedCrossRef Stern SE et al (2005) Identification of individuals with insulin resistance using routine clinical measurements. Diabetes 54(2):333–339PubMedCrossRef
25.
Zurück zum Zitat Eder L et al (2012) Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their correlation with disease activity. Ann Rheum Dis (In Press). Eder L et al (2012) Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their correlation with disease activity. Ann Rheum Dis (In Press).
26.
Zurück zum Zitat Han C et al (2006) Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 33(11):2167–2172PubMed Han C et al (2006) Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 33(11):2167–2172PubMed
27.
Zurück zum Zitat Hertle E, van Greevenbroek MM, Stehouwer CD (2012) Complement C3: an emerging risk factor in cardiometabolic disease. Diabetologia 55(4):881–884PubMedCentralPubMedCrossRef Hertle E, van Greevenbroek MM, Stehouwer CD (2012) Complement C3: an emerging risk factor in cardiometabolic disease. Diabetologia 55(4):881–884PubMedCentralPubMedCrossRef
28.
Zurück zum Zitat Yang S et al (2011) Serum complement C3 has a stronger association with insulin resistance than high-sensitivity C-reactive protein in women with polycystic ovary syndrome. Fertil Steril 95(5):1749–1753PubMedCrossRef Yang S et al (2011) Serum complement C3 has a stronger association with insulin resistance than high-sensitivity C-reactive protein in women with polycystic ovary syndrome. Fertil Steril 95(5):1749–1753PubMedCrossRef
29.
Zurück zum Zitat Wang B et al (2011) Serum complement C3 has a stronger association with insulin resistance than high sensitive C-reactive protein in non-diabetic Chinese. Inflamm Res 60(1):63–68PubMedCrossRef Wang B et al (2011) Serum complement C3 has a stronger association with insulin resistance than high sensitive C-reactive protein in non-diabetic Chinese. Inflamm Res 60(1):63–68PubMedCrossRef
30.
Zurück zum Zitat Muscari A et al (2007) Serum C3 is a stronger inflammatory marker of insulin resistance than C-reactive protein, leukocyte count, and erythrocyte sedimentation rate: comparison study in an elderly population. Diabetes Care 30(9):2362–2368PubMedCrossRef Muscari A et al (2007) Serum C3 is a stronger inflammatory marker of insulin resistance than C-reactive protein, leukocyte count, and erythrocyte sedimentation rate: comparison study in an elderly population. Diabetes Care 30(9):2362–2368PubMedCrossRef
31.
Zurück zum Zitat Baldo A et al (1993) The adipsin-acylation stimulating protein system and regulation of intracellular triglyceride synthesis. J Clin Invest 92(3):1543–1547PubMedCentralPubMedCrossRef Baldo A et al (1993) The adipsin-acylation stimulating protein system and regulation of intracellular triglyceride synthesis. J Clin Invest 92(3):1543–1547PubMedCentralPubMedCrossRef
32.
Zurück zum Zitat Maslowska M et al (1999) Plasma acylation stimulating protein, adipsin and lipids in non-obese and obese populations. Eur J Clin Invest 29(8):679–686PubMedCrossRef Maslowska M et al (1999) Plasma acylation stimulating protein, adipsin and lipids in non-obese and obese populations. Eur J Clin Invest 29(8):679–686PubMedCrossRef
33.
Zurück zum Zitat Faraj M et al (2003) Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 88(4):1594–1602PubMedCrossRef Faraj M et al (2003) Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 88(4):1594–1602PubMedCrossRef
34.
Zurück zum Zitat Kalant D et al (2005) C5L2 is a functional receptor for acylation-stimulating protein. J Biol Chem 280(25):23936–23944PubMedCrossRef Kalant D et al (2005) C5L2 is a functional receptor for acylation-stimulating protein. J Biol Chem 280(25):23936–23944PubMedCrossRef
35.
Zurück zum Zitat Cianflone K et al (1994) Adipsin/acylation stimulating protein system in human adipocytes: regulation of triacylglycerol synthesis. Biochemistry 33(32):9489–9495PubMedCrossRef Cianflone K et al (1994) Adipsin/acylation stimulating protein system in human adipocytes: regulation of triacylglycerol synthesis. Biochemistry 33(32):9489–9495PubMedCrossRef
36.
Zurück zum Zitat Van Harmelen V et al (1999) Mechanisms involved in the regulation of free fatty acid release from isolated human fat cells by acylation-stimulating protein and insulin. J Biol Chem 274(26):18243–18251PubMedCrossRef Van Harmelen V et al (1999) Mechanisms involved in the regulation of free fatty acid release from isolated human fat cells by acylation-stimulating protein and insulin. J Biol Chem 274(26):18243–18251PubMedCrossRef
37.
Zurück zum Zitat Germinario R et al (1993) Coordinate regulation of triacylglycerol synthesis and glucose transport by acylation-stimulating protein. Metabolism 42(5):574–580PubMedCrossRef Germinario R et al (1993) Coordinate regulation of triacylglycerol synthesis and glucose transport by acylation-stimulating protein. Metabolism 42(5):574–580PubMedCrossRef
38.
Zurück zum Zitat Volanakis JE (1995) Transcriptional regulation of complement genes. Annu Rev Immunol 13:277–305PubMedCrossRef Volanakis JE (1995) Transcriptional regulation of complement genes. Annu Rev Immunol 13:277–305PubMedCrossRef
39.
Zurück zum Zitat Peake PW et al (1997) Detection and quantification of the control proteins of the alternative pathway of complement in 3T3-L1 adipocytes. Eur J Clin Invest 27(11):922–927PubMedCrossRef Peake PW et al (1997) Detection and quantification of the control proteins of the alternative pathway of complement in 3T3-L1 adipocytes. Eur J Clin Invest 27(11):922–927PubMedCrossRef
40.
Zurück zum Zitat Gabrielsson BG et al (2003) High expression of complement components in omental adipose tissue in obese men. Obes Res 11(6):699–708PubMedCrossRef Gabrielsson BG et al (2003) High expression of complement components in omental adipose tissue in obese men. Obes Res 11(6):699–708PubMedCrossRef
41.
Zurück zum Zitat Peters MJ et al (2010) EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69(2):325–331PubMedCrossRef Peters MJ et al (2010) EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69(2):325–331PubMedCrossRef
42.
Zurück zum Zitat Mok CC et al (2011) Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. Arthritis Care Res (Hoboken) 63(2):195–202CrossRef Mok CC et al (2011) Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. Arthritis Care Res (Hoboken) 63(2):195–202CrossRef
43.
Zurück zum Zitat Chimenti MS et al (2012) Complement system in psoriatic arthritis: a useful marker in response prediction and monitoring of anti-TNF treatment. Clin Exp Rheumatol 30(1):23–30PubMed Chimenti MS et al (2012) Complement system in psoriatic arthritis: a useful marker in response prediction and monitoring of anti-TNF treatment. Clin Exp Rheumatol 30(1):23–30PubMed
Metadaten
Titel
Serum complement C3 correlates with insulin resistance in never treated psoriatic arthritis patients
verfasst von
Francesco Ursini
Alessandro Grembiale
Saverio Naty
Rosa Daniela Grembiale
Publikationsdatum
01.12.2014
Verlag
Springer London
Erschienen in
Clinical Rheumatology / Ausgabe 12/2014
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-013-2366-4

Weitere Artikel der Ausgabe 12/2014

Clinical Rheumatology 12/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.